These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35256324)

  • 1. Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Küçükarda A; Gökyer A; Gökmen I; Özcan E; Hacıoğlu MB; Erdoğan B; Uzunoğlu S; Çiçin I
    Actas Urol Esp (Engl Ed); 2022 Jun; 46(5):301-309. PubMed ID: 35256324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
    Yamada Y; Matsubara N; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S
    BMC Res Notes; 2016 Oct; 9(1):471. PubMed ID: 27756383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer.
    La J; Wang L; Corrigan JK; Lang D; Lee MH; Do NV; Brophy MT; Paller CJ; Fillmore NR
    JAMA Netw Open; 2024 Aug; 7(8):e2428444. PubMed ID: 39150709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide.
    Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
    Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive significance of inflammatory markers and mGPS in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Goktas Aydin S; Kutlu Y; Muglu H; Aydin A; Acikgoz O; Hamdard J; Karci E; Bilici A; Olmez OF; Yildiz O
    Cancer Chemother Pharmacol; 2024 Jan; 93(1):71-78. PubMed ID: 37773537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
    Khalaf DJ; Aragón IM; Annala M; Lozano R; Taavitsainen S; Lorente D; Finch DL; Romero-Laorden N; Vergidis J; Cendón Y; Oja C; Pacheco MI; Zulfiqar M; ; Gleave ME; Wyatt AW; Olmos D; Chi KN; Castro E
    Ann Oncol; 2020 Sep; 31(9):1186-1197. PubMed ID: 32574722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.
    Yu EY; Berry WR; Gurney H; Retz M; Conter HJ; Laguerre B; Fong PCC; Ferrario C; Todenhöfer T; Gravis G; Piulats JM; Emmenegger U; Shore ND; Romano E; Mourey L; Li XT; Poehlein CH; Schloss C; Appleman LJ; de Bono JS
    Eur Urol Oncol; 2024 Jun; 7(3):509-518. PubMed ID: 37940446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Tseng CS; Yang JH; Huang SW; Wang YJ; Chen CH; Pu YS; Cheng JC; Huang CY
    BMC Cancer; 2023 Jun; 23(1):568. PubMed ID: 37340337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.
    Fan L; Wang X; Chi C; Wang Y; Cai W; Shao X; Xu F; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Wang R; Zhou L; Dong B; Xue W
    Prostate; 2017 Sep; 77(12):1233-1241. PubMed ID: 28752926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR; Saad F; Rathkopf DE; Mulders PFA; de Bono JS; Small EJ; Shore ND; Fizazi K; Kheoh T; Li J; De Porre P; Todd MB; Yu MK; Ryan CJ
    Eur Urol; 2017 Jul; 72(1):10-13. PubMed ID: 28314611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
    Yazgan SC; Yekedüz E; Utkan G; Ürün Y
    Prostate; 2022 Nov; 82(15):1456-1461. PubMed ID: 35899494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients.
    Efstathiou E; Titus M; Wen S; Troncoso P; Hoang A; Corn P; Prokhorova I; Araujo J; Dmuchowski C; Melhem-Bertrandt A; Patil S; Logothetis CJ
    Eur Urol Oncol; 2020 Feb; 3(1):119-127. PubMed ID: 31412017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
    Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
    ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
    Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
    Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
    Kawahara T; Kato M; Tabata K; Kojima I; Yamada H; Kamihira O; Tsumura H; Iwamura M; Uemura H; Miyoshi Y
    BMC Cancer; 2020 Sep; 20(1):919. PubMed ID: 32977754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.